What is value in today’s oncology market? This is a question dividing pharma, payers, providers, and patients. At a time when drug reimbursement is a continuously changing landscape, it is more important than ever to align all stakeholders on a common definition.
Back for a 7th year, eyeforpharma Oncology Leadership Summit (June 16-17) brings together all stakeholders, including pharma, insurance companies, patient advocacy groups, and cancer associations to bridge the gap on the differing views of “value”.
This year we will widely be discussing the various value-based pricing metrics to hear why payers are hungry for these models and how they may leverage them, and which metrics will make a significant impact on the market access environment for drugs and biologics in cancer.
Here we will help you determine how to best position your brand in an evolving market, and how to cross-functionally work with teams to address the challenges these metrics bring. This will enable you to have a stronger market access trajectory by better demonstrating your products’ importance.
The debate will be driven by key stakeholders and leading oncology innovators, including:
• Michael Kolodziej, Medical Director, Aetna
• William Hinshaw, EVP, US Oncology, Novartis
• Michael Ryan, SVP, US Value, Access, & Policy, Bristol Myers Squibb
• Richard Schilsky, CMO, ASCO
• Anil Kapur, VP & Global Head of Oncology Commercial, Baxalta